脲原体属。和人型支原体,下泌尿生殖道频繁的定植者,与各种感染有关,随着抗生素耐药性的增长和区域变化。本研究旨在调查脲原体的患病率和抗生素耐药性。杭州门诊病人中的人马,中国,从2013年到2019年。共检查了135,263名门诊患者,以确定脲原体的患病率。和人类M.包括48,638名男性和86,625名女性。此外,脲原体属的抗生素敏感性趋势。分析了1999-2019年的人马。种植,identification,和细菌的抗生素敏感性(氧氟沙星,环丙沙星,红霉素,克拉霉素,阿奇霉素,交沙霉素,四环素,多西环素,和pristinamycin)使用支原体IST2试剂盒测定。我们的研究表明,总脲原体属的总体患病率。/M.从2013年到2019年,hominis为38.1%。脲原体属。是最常见的孤立物种(总体流行,31.3%),其次是脲原体。/M.人类合并感染(6.0%)和单一人类分枝杆菌感染(0.8%)。脲原体的患病率。女性的人源支原体明显高于男性,总脲原体阳性率最高。/M.在14-20岁的女性和男性门诊患者中均观察到了hominis。2013-2019年,交沙霉素,四环素,多西环素,和pristinamycin保持异常高的活性(总体耐药率,<5%)对两种脲原体属。和人类M.但氧氟沙星和环丙沙星显示出有限的活性(总体耐药率,>70%)。在1999-2019年期间,对氧氟沙星和环丙沙星的耐药率对两种脲原体均增加。和人源分枝杆菌,但减少到红霉素,克拉霉素,阿奇霉素,四环素,和多西环素抗脲原体。总之,我们的研究表明,脲原体的患病率很高。与人源支原体和脲原体属物种相比。/M.人类,它们的分布与性别和年龄有关。交沙霉素,多西环素,和四环素是有前途的抗生素,对脲原体和人支原体具有显着的活性。
Ureaplasma spp. and Mycoplasma hominis, frequent colonizers in the lower urogenital tract, have been implicated in various infections, with antibiotic resistance growing and varying regionally. This study aims to investigate the prevalence and antibiotic resistance profiles of Ureaplasma spp. and M. hominis in outpatients in Hangzhou, China, from 2013 to 2019. A total of 135,263 outpatients were examined to determine the prevalence of Ureaplasma spp. and M. hominis, including 48,638 males and 86,625 females. Furthermore, trends in antibiotic susceptibility of Ureaplasma spp. and M. hominis during 1999-2019 were analyzed. The cultivation, identification, and antibiotic susceptibility of the bacteria (ofloxacin, ciprofloxacin, erythromycin, clarithromycin, azithromycin, josamycin, tetracycline, doxycycline, and pristinamycin) were determined using the Mycoplasma IST2 kit. Our study indicated that the overall prevalence of total Ureaplasma spp./M. hominis was 38.1% from 2013 to 2019. Ureaplasma spp. were the most frequently isolated species (overall prevalence, 31.3%), followed by Ureaplasma spp./M. hominis coinfection (6.0%) and single M. hominis infection (0.8%). The prevalence of Ureaplasma spp. and M. hominis was significantly higher in females than in males, and the highest positive rates of total Ureaplasma spp./M. hominis were observed in both female and male outpatients aged 14-20 years. During 2013-2019, josamycin, tetracycline, doxycycline, and pristinamycin maintained exceptionally high activity (overall resistance rates, <5%) against both Ureaplasma spp. and M. hominis, but ofloxacin and ciprofloxacin showed limited activity (overall resistance rates, >70%). During 1999-2019, the rates of resistance to ofloxacin and ciprofloxacin increased against both Ureaplasma spp. and M. hominis but decreased to erythromycin, clarithromycin, azithromycin, tetracycline, and doxycycline against Ureaplasma spp. In conclusion, our study demonstrates a high prevalence of Ureaplasma spp. compared to M. hominis and Ureaplasma spp./M. hominis, and their distribution was associated with sex and age. Josamycin, doxycycline, and tetracycline are promising antibiotics that have remarkable activity against Ureaplasma species and M. hominis.